Evaluation of bone disease in multiple myeloma: A comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios

European Journal of Haematology

Volumn 62, Issue 5, 1999, Pages 300-306

  Carlson, Kristina ^a   Larsson, A ^a   Simonsson, B ^a   Turesson, I ^b   Westin, J ^b   Ljunghall, S ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Deoxypyridinoline; ICTP; Myeloma; Osteocalcin; PICP

Indexed keywords

COLLAGEN TYPE 1; CREATININE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PEPTIDE;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METABOLISM; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOGRAPHY; SEX DIFFERENCE; SURVIVAL RATE; VERTEBRA FRACTURE;

EID: 0032902720     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01906.x     Document Type: Article

References (19)

1. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmocytomas: Direct induction by tumour cells in vivo. Br J Haematol 1995;90:721-724.
2. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-1273.
3. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Int Med 1993;25:385-393.
4. Hassager C, Jensen LT, Johansen JS, et al. The carboxyterminal propeptide of type I procollagen in serum as a marker of bone formation: The effect of nandrolone deconate and female sex hormones. Metabolism 1991;40:205-208.
5. Rosteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone degradation. Clin Chem 1993;39:635-640.
6. Eriksen EF, Charles P, Melsen F, Moskilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res 1993;8:127-132.
7. Bataille R, Delmas P, Sany J. Serum gla-protein in multiple myeloma. Cancer 1987;59:329-334.
8. Carlson K, Ljunghall S, Simonsson B, Smedmyr B. Serum osteocalcin levels in patients with multiple myeloma -correlation with disease stage and survival. J Int Med 1992;231:133-137.
9. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentrations of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-341.
10. Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: Analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol 1994;46:173-178.
11. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum gla protein levels in multiple myeloma: Crucial role of bone formation and prognostic implications. Cancer 1990;66:167-172.
12. Abilgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haematol 1997;96:103-110.
13. Peest D, Deicher H, Fett W, et al. Pyridinium cross-links in multiple myeloma: Correlation with clinical parameters and use for monitoring of intravenous clodronate therapy. A pilot study of the German myeloma treatment group (GMTG). Eur J Cancer 1996;32A:2053-2057.
14. Bettica P, Moro L, Robins SP, et al. Bone resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin Chem 1992;38:2313-2318.
15. Pecherstorfer M, Seibel MJ, Woigte HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by pyridinium cross-links of collagen. Blood 1997;90:3743-3750.
16. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Br J Haematol 1998;101:280-286.
17. Eriksen EF. Normal and pathological remodeling of human trabecular bone. Three-dimensional reconstruction of the remodeling sequence in normal and metabolic bone disease. Endocr Rev 1986;7:379-408.
18. Valentin-Opran A, Chardon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology in myeloma-induced bone changes. Br J Haematol 1982;52:601-610.
19. Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta 1996;253:61-67.